Fezolinetant (Veozah)
Hormones · NK3 receptor antagonist (non-hormonal)
Tier B+
What this is
First-in-class non-hormonal therapy for moderate-to-severe vasomotor symptoms (hot flashes/night sweats) of menopause. Major option for women with breast cancer history or other contraindications to estrogen. Liver-enzyme monitoring requirement is the practical adoption barrier. Astellas; brand Veozah.
Mechanism
Selective neurokinin 3 (NK3) receptor antagonist; blocks NK3 signaling on KNDy neurons in the hypothalamic thermoregulatory center; corrects the dysregulated firing pattern that drives hot flashes after estrogen decline
Dose & route
45 mg PO once daily
Citations
- https://doi.org/10.1007/s40265-025-02231-8
- https://pubmed.ncbi.nlm.nih.gov/40299712/
- https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.